Skip to main content
Log in

A Sensitive Docetaxel Assay in Plasma by Solid-Phase Extraction and High Performance Liquid Chromatography – UV Detection: Validation and Suitability in Phase I Clinical Trial Pharmacokinetics

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

We have developed a specific and sensitive method aiming atdocetaxel (Taxotere®) determination in plasma of treatedpatients. This involved solid-phase extraction of 1 ml of plasmaonto carboxylic acid (CBA) grafted silica cartridges followed byreversed-phase liquid chromatography with UV detection. The bestselectivity was obtained through the use of C18 Uptisphere® asstationary phase. The low limit of quantitation obtained (LOQ:5 ng/ml) allowed measurements of docetaxel up to 24 hours afterone-hour infusions with low dosages of drug (60 mg/m2). Themethod was applied successfully to monitor docetaxel plasma levelswithin two protocols associating fixed dosages of either methotrexate or gemcitabine with escalating doses of Taxotere®.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F, Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT: Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51: 4845–4852, 1991

    Google Scholar 

  2. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB: Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16: 187–196, 1998

    Google Scholar 

  3. Vogel M, Hilsenbeck SG, Depenbrock H, Danhauser-Riedl S, Block T, Nekarda H, Fellbaum C, Aapro MS, Bissery MC, Rastetter J et al.: Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents. Eur J Cancer 29A: 2009–20141993

    Google Scholar 

  4. Eckardt JR: Antitumor activity of docetaxel. Am J Health Syst Pharm 54: S2–S6, 1997

    Google Scholar 

  5. Eisenhauer EA, Vermorken JB: The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 55: 5–30, 1998

    Google Scholar 

  6. Ravdin PM: Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients. Eur J Cancer 33 (Suppl 7): S7–S10, 1997

    Google Scholar 

  7. Valero V: Combination docetaxel/cyclophosphamide in patients with advanced solid tumors. Oncology (Huntingt) 11: 34–36, 1997

    Google Scholar 

  8. Aapro MS: Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer. Oncology (Huntingt) 11: 46–49, 1997

    Google Scholar 

  9. Burris HA 3rd: Docetaxel in combination with fluorouracil for advanced solid tumors. Oncology (Huntingt) 11: 50–52, 1997

    Google Scholar 

  10. Dieras V, Fumoleau P, Kalla S, Misset JL, Azli N, Pouillart P: Docetaxel in combination with doxorubicin or vinorelbine. Eur J Cancer 33: S20–S22, 1997

    Google Scholar 

  11. Mauer AM, Masters GA, Haraf DJ, Hoffman PC, Watson SM, Golomb HM, Vokes EE: Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 16: 159–164, 1998

    Google Scholar 

  12. Ardiet C, Zanetta S, Bernard E, Tranchand B, Droz JP: A solid-phase extraction procedure for docetaxel determination in plasma for pharmacokinetic studies (Abstract) 10th NCI-EORTC Symposium on new drugs in cancer therapy. Amsterdam, June 16–19, 1988; no 481 p 125

    Google Scholar 

  13. Vergniol TC, Bruno R, Montay G, Frydman A: Determination of Taxotere in human plasma by a semi-automated highperformance liquid chromatographic method. J Chromatogr 582: 273–278, 1992

    Google Scholar 

  14. Hempel G, Lehmkuhl D, Krumpelmann S, Blaschke G, Boos J: Determination of paclitaxel in biological fluids by micellar electrokinetic chromatography. J Chromatogr A 745: 173–179, 1996

    Google Scholar 

  15. Loos WJ, Verweij J, Nooter K, Stoter G, Sparreboom A: Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 693: 437–441, 1997

    Google Scholar 

  16. Rosing H, Lustig V, Koopman FP, ten Bokkel Huinink WW, Beijnen JH: Bio-analysis of docetaxel and hydroxylated metabolites in human plasma by high-performance liquid chromatography and automated solid-phase extraction. J Chromatogr B Biomed Sci Appl 696: 89–98, 1997

    Google Scholar 

  17. Guillot A, Ardiet C, Dumortier A, Zanetta S, Rebattu P, Dubin F, Assadourian S, Droz JP: Phase I trial of docetaxel and methotrexate combination in patients with metastatic and urothelial epidermoid carcinoma (Abstract). 10th NCI-EORTC Symposium on new drugs in cancer therapy. Amsterdam, June 16–19, 1988; no 395, p 103

    Google Scholar 

  18. Bissery MC, Vrignaud P, Bayssas M, Lavelle F: Preclinical in vivoactivity of docetaxel-containing combinations. Proc Am Soc Clin Oncol 14: 489, 1995

    Google Scholar 

  19. Rebattu P, Pujol JL, Ardiet C, Quentin X, Droz JP, Dumortier A, Khial F, Schuller MP: Combination of docetaxel (DTX) and gemcitabine (G) in patients with inoperable or metastatic non-small cell lung cancer (NSCLC). A phase I study. (Abstract) 10th NCI-EORTC Symposium on new drugs in cancer therapy. Amsterdam June 16–19, 1988; no 361, p 95

    Google Scholar 

  20. Warner A, Privitera M, Bates D: Standards of laboratory practice: antiepileptic drug monitoring. National Academy of Clinical Biochemistry. Clin Chem 44: 1085–1095, 1998

    Google Scholar 

  21. Valdes R Jr, Jortani SA, Gheorghiade M: Standards of laboratory practice: cardiac drug monitoring. National Academy of Clinical Biochemistry. Clin Chem 44: 1096–1109, 1998

    Google Scholar 

  22. Glantz MJ, Choy H, Akerley W, Kearns CM, Egorin MJ, Rhodes CH, Cole BF: Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response. Semin Oncol 23: 128–135, 1996

    Google Scholar 

  23. Boos J: Ist die Pharmakokinetik von Cytarabin klinisch relevant? Klin Padiatr 204: 198–203, 1992

    Google Scholar 

  24. Ratain MJ, Mick R: Principles of pharmacokinetics and pharmacodynamics. In: Schilsky RL, Milano GA, Ratain MJ (eds) Principles of Antineoplastic Drug Development and Pharmacology. Marcel Dekker, Inc. 1996, pp 123–141

  25. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB: Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16: 187–196, 1998

    Google Scholar 

Download references

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Joseph Ardiet, C., Tranchand, B., Zanetta, S. et al. A Sensitive Docetaxel Assay in Plasma by Solid-Phase Extraction and High Performance Liquid Chromatography – UV Detection: Validation and Suitability in Phase I Clinical Trial Pharmacokinetics. Invest New Drugs 17, 325–333 (1999). https://doi.org/10.1023/A:1006327302041

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006327302041

Navigation